Xolair (omalizumab) is a prescription drug that’s used to treat certain conditions, including asthma. Xolair can cause side effects that range from mild to serious. Examples include injection ...

Jasper Therapeutics, a biotech looking to make stem cell transplants less taxing and to treat immune-mediated diseases, reported on Monday that its experimental drug helped patients with a chronic ...

Xolair (omalizumab) was approved to reduce allergic reactions ... therapies for food allergy are being assessed in clinical trials. A drug with a similar mechanism is Dupixent, a biologic that targets ...

The European Commission (EC) has approved AstraZeneca's Fasenra (benralizumab) as an add-on therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA), a ...

New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids AstraZeneca’s Fasenra (benralizumab) ...

An international team of neuroscientists, led by Duke-NUS Medical School, have uncovered a mechanism that controls the reactivation of neural stem cells, which are crucial for repairing and ...

The European Commission has approved the Committee for Medicinal Products for Human Use (CHMP) recommendation to change the terms of marketing authorization for Fasenra (benralizumab). It can now ...

AstraZeneca’s (AZN) Fasenra has been approved in the European Union, EU, as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...